EA201490105A1 - Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности - Google Patents

Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности

Info

Publication number
EA201490105A1
EA201490105A1 EA201490105A EA201490105A EA201490105A1 EA 201490105 A1 EA201490105 A1 EA 201490105A1 EA 201490105 A EA201490105 A EA 201490105A EA 201490105 A EA201490105 A EA 201490105A EA 201490105 A1 EA201490105 A1 EA 201490105A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
kidney damage
prediction
diagnosis
Prior art date
Application number
EA201490105A
Other languages
English (en)
Inventor
Джозеф Андерберг
Джефф Грей
Пол Макферсон
Кевин Накамура
Джеймс Патрик Кампф
Original Assignee
Астьют Медикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астьют Медикал, Инк. filed Critical Астьют Медикал, Инк.
Publication of EA201490105A1 publication Critical patent/EA201490105A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к способам и композициям для наблюдения за состоянием, диагностики, прогнозирования и определения схемы лечения субъектов, страдающих повреждением почек или предположительно имеющих повреждение почек. В частности, настоящее изобретение относится к применению одного или более анализов, позволяющих обнаружить маркер повреждения почек, выбранный из группы, состоящей из белка теплового шока β-1, белка 2, содержащего коровый домен кислого белка молочной сыворотки (WAP) с четырьмя дисульфидными связями, β-субъединицы хориогонадотропина, фактора роста плаценты и митохондриального белка теплового шока массой 60 кДа в качестве диагностических и прогностических биомаркеров при повреждениях почек.
EA201490105A 2011-07-09 2012-07-05 Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности EA201490105A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506038P 2011-07-09 2011-07-09
PCT/US2012/045583 WO2013009573A1 (en) 2011-07-09 2012-07-05 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
EA201490105A1 true EA201490105A1 (ru) 2014-07-30

Family

ID=47506416

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490105A EA201490105A1 (ru) 2011-07-09 2012-07-05 Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности

Country Status (9)

Country Link
US (2) US20140171522A1 (ru)
EP (1) EP2729803A4 (ru)
JP (1) JP2014521088A (ru)
CN (1) CN103858008B (ru)
AU (1) AU2012282918A1 (ru)
CA (1) CA2841880A1 (ru)
EA (1) EA201490105A1 (ru)
MX (1) MX2014000283A (ru)
WO (1) WO2013009573A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014120569A1 (en) * 2013-01-25 2014-08-07 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for human epididymis protein-4 (he4)
EP3074122A4 (en) 2013-11-27 2017-11-29 Bio-Rad Laboratories, Inc. Microfluidic droplet packing
CN104045453B (zh) * 2014-06-11 2016-08-24 句容市鑫诚果业家庭农场 一种石榴专用有机肥料及其制备方法
WO2015195698A1 (en) 2014-06-16 2015-12-23 Gnubio, Inc. Size alternating injection into drops to facilitate sorting
CN104062294A (zh) * 2014-07-11 2014-09-24 青岛千士医疗科技有限公司 一种支气管/肺上皮细胞线粒体损伤的检测方法
CN104166003B (zh) * 2014-08-06 2016-06-08 中国人民解放军第二军医大学 人附睾蛋白4在制备系统性红斑狼疮性肾病诊断试剂或试剂盒中的应用
WO2016130802A1 (en) * 2015-02-11 2016-08-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
TW201827070A (zh) * 2016-12-19 2018-08-01 康鶴生醫科技股份有限公司 合成多肽、含該多肽的組合物、由其產生的抗體及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7347300A (en) * 1999-09-02 2001-03-26 Gene Logic, Inc. Modulation of he4 in inflammatory and renal diseases
CN1791797A (zh) * 2003-03-27 2006-06-21 儿童医院医疗中心 用于检测肾小管细胞损伤的早发的方法和试剂盒
US7588892B2 (en) * 2004-07-19 2009-09-15 Entelos, Inc. Reagent sets and gene signatures for renal tubule injury
US20070087387A1 (en) * 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
EP2500723B1 (en) * 2006-11-14 2015-07-08 Alere San Diego, Inc. Methods for monitoring and risk prediction in cardiorenal syndrome
JP2010520768A (ja) * 2007-03-09 2010-06-17 トライパス イメージング インコーポレイテッド Ｈｅ４モノクローナル抗体およびそれらの使用方法
WO2008116867A1 (en) * 2007-03-26 2008-10-02 Novartis Ag Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
CN101960308B (zh) * 2008-02-29 2014-07-09 国立大学法人名古屋大学 急性肾损伤及预后推测用生物标记物以及其用途
US20090234202A1 (en) * 2008-03-05 2009-09-17 Goix Philippe J Method and compositions for highly sensitive detection of molecules
US20110143366A1 (en) * 2008-06-04 2011-06-16 Proteosys Ag Protein biomarkers for in vitro testing of developmental toxicity and enbryotoxicity of chemical substances
CN102187220B (zh) * 2008-08-28 2015-08-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CA2743253A1 (en) * 2008-11-22 2010-05-27 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX342967B (es) * 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
US20120329071A1 (en) * 2010-03-05 2012-12-27 Mark Chance Protein biomarkers and therapeutic targets for renal disorders
EP2646822B1 (en) * 2010-11-29 2017-11-01 Alere San Diego, Inc. Methods for diagnosis and risk prediction in heart failure
EP2729181A4 (en) * 2011-07-06 2014-12-17 Alere San Diego Inc METHOD AND COMPOSITIONS FOR CALCULATING THE PROBABILITY OF PROGRESSION OF ACUTE CHILD LENGTH

Also Published As

Publication number Publication date
MX2014000283A (es) 2014-05-01
AU2012282918A1 (en) 2014-02-06
JP2014521088A (ja) 2014-08-25
EP2729803A1 (en) 2014-05-14
WO2013009573A1 (en) 2013-01-17
CN103858008B (zh) 2017-03-01
US20140171522A1 (en) 2014-06-19
EP2729803A4 (en) 2015-08-05
CN103858008A (zh) 2014-06-11
US20160097779A1 (en) 2016-04-07
CA2841880A1 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
EA201490105A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201290711A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201290629A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201490384A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201290056A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
NZ630277A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ625423A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012174282A3 (en) Biomarker compositions and methods
WO2013022995A3 (en) Biomarker compositions and methods
WO2013134786A3 (en) Biomarker compositions and methods
EP2767833A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010057184A3 (en) Methods for detection of acute kidney injury in humans
JP2017524130A5 (ru)
WO2010022210A3 (en) Diagnosis and monitoring of renal failure using peptide biomarkers
NZ592358A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure using tissue inhibitor of metalloproteinase 2 (timp-2)
EA201290192A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
MX2011008323A (es) Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
EA201291314A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201290195A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
BR112015014232A2 (pt) lesão renal aguda
EA201790696A1 (ru) Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201290106A1 (ru) Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
WO2011097541A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112012024175A2 (pt) hbf e a1m como marcadores de estágio precoce para preeclampsia